Syntara the science explained, page-52

Jeeeez thanks @kpax , there's a lot to digest within SNT .

My acumen says this company are heading in the right direction ,,, you couldn't ask for more from Multiple Previous Phase I Trials,
"The inhibitors have shown excellent clinical safety and tolerability."


Syntara has developed both oral and topical pan-LOX inhibitors, allowing for diverse applications in different conditions.
"Simple Tablets or Cream"


Their mode of action complements current standard treatments, potentially enhancing overall efficacy.
These inhibitors show promise in various indications, including
" myelofibrosis, myelodysplastic syndrome, skin fibrosis, and solid tumors."Plus December for the "Data Presentation in the United States.." NZT
Gary Spoke for 20mins on Saturday , so looking forward to the Presentation Video being posted .

Session 7: Second Pass | Time for a Re-Assessment Some familiar companies are presenting in this session, with most having re-directed their business plan, their disease focus or market application over the last decade.
Their new products in development or new market applications for products may warrant a second pass to look at these stocks. 2.00pm - 2.20pm 2 Gary Phillips, CEO of Syntara (formerly Pharmaxis)

Our Event Partner for the Summit is the WA Government and our Destination Sponsor is Business Events Perth.
Over 200 Attendees Sophs and Insto's